Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Revisit Every OncLive On Air Episode From February 2025

March 3rd 2025

Read a recap of the episodes of OncLive On Air that aired in February 2025.

CHMP Recommends Subcutaneous Daratumumab Plus VRd for Newly Diagnosed Myeloma

February 28th 2025

The CHMP has recommend the approval of subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma.

CHMP Recommends Approval of Glofitamab Plus Chemotherapy for R/R DLBCL

February 28th 2025

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

Pirtobrutinib Earns Positive CHMP Opinion for R/R CLL After a Covalent BTK Inhibitor

February 28th 2025

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

CHMP Recommends Conditional Approval of Linvoseltamab for R/R Multiple Myeloma

February 28th 2025

The CHMP has issued a positive opinion for linvoseltamab in relapsed/refractory multiple myeloma.

T-DXd Receives Positive CHMP Opinion for HER2-Low or HER2-Ultralow Metastatic Breast Cancer

February 28th 2025

The CHMP has recommended the approval of trastuzumab deruxtecan for HER2-low or HER2-ultralow metastatic breast cancer.

Etentamig With Step-Up Dosing Shows Preliminary Efficacy, Safety in R/R Myeloma

February 27th 2025

Step-up dosing with etentamig produced responses and low rates of CRS in relapsed/refractory multiple myeloma.

Dr DeAngelo on the Importance of Consensus Guidelines for Treating Acute Lymphoblastic Leukemia

February 26th 2025

Daniel DeAngelo, MD, PhD, discusses the need for consensus guidelines in the management of ALL, particularly in defining optimal treatment strategies for older adult patients.

Dr Shadman on the Need for a Clinical Consensus in the Evolving Treatment Landscape of DLBCL

February 26th 2025

Mazyar Shadman, MD, MPH, discusses the need for a clinical consensus in selecting optimal treatment strategies in diffuse large B-cell lymphoma.

Dr Komrokji on the Importance of Establishing a Clinical Consensus Regarding the Use of Molecular Testing in MDS

February 26th 2025

Rami Komrokji, MD, discusses the importance of establishing a clinical consensus to standardize the use of molecular testing in myelodysplastic syndromes.

Dr Krishnan on the Complexity of Developing a Consensus for Risk Stratification in Smoldering Myeloma

February 26th 2025

Amrita Krishnan, MD, discusses the challenges in developing a clinical consensus on risk stratification in smoldering multiple myeloma and its role in guiding treatment decisions.

Dr Fisch on the Incidence of Neutropenia With Sacituzumab Govitecan in Advanced Breast Cancer

February 26th 2025

Samantha Fisch, MD, discusses rates of neutropenia in patients with advanced breast cancer treated with sacituzumab govitecan.

Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies

February 25th 2025

Mohammed Najeeb Al Hallak, MD, MS explores treatment considerations in advanced pancreatic, colorectal, and neuroendocrine cancers.

Dr Randall on the Utility of Intraoperative Peripheral Margin Assessment in Soft Tissue Sarcomas

February 24th 2025

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen margin assessment in soft tissue sarcoma.

Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

February 24th 2025

Yelena Y. Janjigian, MD, discusses 5-year follow-up findings for nivolumab plus chemotherapy vs chemotherapy alone in gastric/GEJ adenocarcinoma.

Dr Cortese on the Role of Venetoclax in CLL Immune Synapse Repair

February 21st 2025

Matthew Cortese, MD, MPH, discusses the immunologic changes observed with venetoclax in patients with CLL.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL

February 21st 2025

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

February 21st 2025

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.

FDA Approval Insights: Mirdametinib for NF1-Associated Plexiform Neurofibromas: With Christopher L. Moertel, MD

February 20th 2025

Christopher L. Moertel, MD, discusses the significance of the FDA approval of mirdametinib, based on efficacy and safety data from the phase 2 ReNeu trial.